The combination of IL-18 blocking agent (IL-18 BP) with the hypoxic BXPC-3 conditioned medium (CM) confirmed that 8 inhibits pancreatic cancer angiogenesis by suppressing IL-18 release. This evidence concerns the gene IL18 and pancreatic neoplasm.